Journal article
VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours
- Abstract:
- Purpose: A major issue for the effective treatment of brain metastasis is the late stage of diagnosis with existing clinical tools. The aim of this study was to evaluate the potential of vascular cell adhesion molecule-1 (VCAM-1) targeted magnetic resonance imaging (MRI) for early detection of brain micrometastases in mouse models across multiple primary tumour types. Experimental Design: Xenograft models of brain micrometastasis for human breast carcinoma (MDA231Br-GFP), lung adenocarcinoma (SEBTA-001) and melanoma (H1_DL2) were established via intracardiac injection in mice. Animals (n=5-6/group) were injected intravenously with VCAM-1 targeted microparticles of iron oxide (VCAM-MPIO) and, subsequently, underwent T2*-weighted MRI. Control groups of naïve mice injected with VCAM-MPIO and tumour-bearing mice injected with non-targeting IgG-MPIO were included. Results: All models showed disseminated micrometastases in the brain, together with endothelial VCAM-1 upregulation across the time-course. T2*-weighted MRI of all tumour-bearing mice injected with VCAM-MPIO showed significantly more signal hypointensities (p<0.001; two-sided) than control cohorts, despite a lack of blood-brain barrier impairment. Specific MPIO binding to VCAM-1 positive tumour-associated vessels was confirmed histologically. VCAM-1 expression was demonstrated in human brain metastasis samples, across all three primary tumour types. Conclusions: VCAM-1-targeted MRI enables detection of brain micrometastases from the three primary tumour types known to cause the majority of clinical cases. These findings represent an important step forward in the development of a broadly applicable and clinically relevant imaging technique for early diagnosis of brain metastasis, with significant implications for improved patient survival.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 259.0KB, Terms of use)
-
- Publisher copy:
- 10.1158/1078-0432.CCR-18-1889
Authors
+ Cancer Research
More from this funder
- Funding agency for:
- Soto, M
- Funding agency for:
- Khrapitchev, A
- Funding agency for:
- Balderas, F
- Funding agency for:
- Sibson, N
- Grant:
- C5255/A15935
- Grant:
- C5255/A15935
- Grant:
- C5255/A15935
- Grant:
- C5255/A15935
+ Cancer Research/ Medical Research Council
More from this funder
- Funding agency for:
- Cheng, VWT
- Grant:
- Clinical research fellowship
- Publisher:
- American Association for Cancer Research
- Journal:
- Clinical Cancer Research More from this journal
- Volume:
- 25
- Issue:
- 2
- Publication date:
- 2018-11-02
- Acceptance date:
- 2018-10-30
- DOI:
- EISSN:
-
1557-3265
- ISSN:
-
1078-0432
- Keywords:
- Pubs id:
-
pubs:937120
- UUID:
-
uuid:3eaa73a4-cc50-4f95-9034-f7dbaf31fbdb
- Local pid:
-
pubs:937120
- Source identifiers:
-
937120
- Deposit date:
-
2018-11-05
- ARK identifier:
Terms of use
- Copyright holder:
- American Association for Cancer Research
- Copyright date:
- 2018
- Notes:
- ©2018, American Association for Cancer Research. This is the accepted manuscript] version of the article. The final version is available online from American Association for Cancer Research at: 10.1158/1078-0432.CCR-18-1889
If you are the owner of this record, you can report an update to it here: Report update to this record